2018 HIDRADENITIS SUPPURATIVA VIDEO ROUNDTABLE

Hidradenitis suppurativa (HS) is a chronic, non-contagious skin disease that causes acne-like boils to form in folds of skin, particularly in the axilla and groin areas. In this video series, Drs. Jerry Bagel, Donnica Moore, Lauren Orenstein, and George Han sit down to discuss the impact that HS has on quality of life, how specialty physicians can work together for improved outcomes, clinical trials, and the roles of biologics and other therapies.

Disclosure: The faculty received modest honoraria from the Custom Programs division of Frontline Medical Communications for their time participating in this roundtable. The faculty was solely responsible for the content presented.

Video 1 of 4: Quality of Life for the HS Patient

In this video, the faculty discuss how the painful, bothersome symptoms of HS affect patents’ quality of life and interfere with their day-to-day physical activities. The faculty also discuss how HS psychologically affects some patients, and how hygiene and lifestyle choices, such as smoking, contribute to HS symptoms.

Up Next

Video 1 of 4: Quality of Life for the HS Patient
Video 2 of 4: How Multi-Specialties Can Work Together for Improved Outcomes
Video 3 of 4: HS Clinical Trials
Video 4 of 4: The Role of Biologics and Other Therapies

About the Panel

Jerry Bagel, MD (Moderator)

  • Director, Psoriasis Treatment Center of Central New Jersey

Donnica Moore, MD

  • Founder and President of Sapphire Women’s Health Group LLC

Lauren Orenstein, MD

  • Assistant Professor, Dermatology, Temple University Lewis Katz School of Medicine

George Han, MD, PhD

  • Chair of the Department of Dermatology, Mount Sinai Beth Israel

This video roundtable was produced by the Custom Programs division of Frontline Medical Communications.

The editorial staff of Dermatology News was not involved in developing the video roundtable.

Dr. Bagel is a consultant for AbbVie, Celgene, Eli Lilly and Company, LEO Pharma, and Novartis.

Drs. Han, Moore and Orenstein do not report any disclosures.